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Preamble 
It is becoming more apparent each day that despite a strong 
national commitment to excellence in health care, the re- 
sources and personnel are finite. It is, therefore, appropriate 
that the medical profession examine the impact of develop- 
ing technology on the practice and cost of medical care. 
Such analysis, carefully conducted, could potentially impact 
on the cost of medical care without diminishing the effec- 
tiveness of that care. 
To this end, the American College of Cardiology and the 
American Heart Association in 1980 established a Task 
Force on Assessment of Diagnostic and Therapeutic Cardio- 
vascular Procedures with the following charge: 
Address for reorints: Michael Forcinito, Special Projects, American 
College of Cardiology. 9111 Old Georgetown Road, Bethesda, Maryland 
20814. 
Guidelines for Clinical Intracardiac Electrophysiologic Studies were 
approved by the American College of Cardiology Board of Trustees on March 
19, 1989 and by the American Heart Association Steering Committee on June 
9, 1989. 
0 1989 by the American College of Cardiology 
The Task Force of the American College of Cardiology and 
the American Heart Association shall define the role of 
specific noninvasive and invasive procedures in the diag- 
nosis and management of cardiovascular disease. 
The Task Force shall address, when appropriate, the contri- 
bution. uniqueness, sensitivity, specificity, indications, 
contraindications and cost-effectiveness of such specific 
procedures. 
The Task Force shall include a Chairman and six members, 
three representatives from the American Heart Associa- 
tion and three representatives from the American College 
of Cardiology. The Task Force may select ad hoc mem- 
bers as needed upon the approval of the Presidents of both 
organizations. Recommendations of the Task Force are 
forwarded to the President of each organization. 
The members of the Task Force are: Roman W. DeSanc- 
tis, MD, Harold T. Dodge, MD, Harriet P. Dustan, MD, J. 
Ward Kennedy, MD, T. Joseph Reeves, MD, Sylvan Lee 
Weinberg, MD and Charles Fisch, MD, Chairman. 
This document was reviewed by the officers and other 
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responsible individuals of the two organizations and received 
final approval in June 1989. It is being published simulta- 
neously in Circulation and the Journal of the American 
College ofcardiology. The potential impact of this document 
on the practice of cardiology and some of its unavoidable 
shortcomings are clearly set out in the introduction. 
Charles Fisch, MD, FACC 
I. Introduction 
During the past 20 years, cardiac electrophysiologic stud- 
ies have evolved into widely employed clinical tools, often 
indispensable in evaluating patients with specific cardiac 
arrhythmias. Because such studies carry a tangible, though 
minimal, risk and are expensive in terms of personnel and 
equipment, it is important that their clinical usefulness for 
the diagnosis and therapy of cardiac arrhythmias be carefully 
considered. This document presents current opinion regard- 
ing the clinical application of invasive cardiac electrophysi- 
ologic studies and is an extension of previous efforts in this 
area (1,2). The American College of Cardiology and the 
American Heart Association recognize that the ultimate 
judgment regarding the propriety of any specific procedure is 
the responsibility of the physician caring for the patient. 
Therefore, these guidelines should not be considered all 
inclusive or exclusive of other methods that may be available 
for the care of the individual patient. Finally, it is important 
to emphasize that this document may require periodic up- 
dating as the indications for electrophysiologic studies con- 
tinue to evolve. 
Conditions for which electrophysiologic studies are fre- 
quently performed but there is less certainty regarding the 
usefulness of the information that is obtained. Experts are 
divided in their opinion as to whether patients with these 
conditions should undergo electrophysiologic study. 
Class III 
Conditions for which there is general agreement that 
electrophysiologic studies do not provide useful information. 
Experts agree that electrophysiologic studies are not war- 
ranted in patients with these conditions. 
It is assumed, for the purposes of this document, that the 
electrophysiologic studies are performed by appropriately 
trained and qualified personnel in adequately equipped lab- 
oratories (3) and that complete electrophysiologic studies, 
indicated by the patient’s clinical state and the arrhythmia in 
question, are performed. In general, such studies include 
intravenous or intraarterial placement, or both, of one or 
more electrode catheters at one or more sites in the atria, 
ventricles or coronary sinus (occasionally in the pulmonary 
artery or aorta) to record or stimulate at various rates and 
cadences. Such studies are performed to evaluate electro- 
physiologic properties such as automaticity, conduction and 
refractoriness, to initiate and terminate tachycardias, to map 
sequence of activation, to evaluate patients for various 
forms of therapy and to judge the response to therapy. 
Studies are modified according to the patient, the problem 
being investigated and the site of the study, i.e., bedside, 
operating room or electrophysiology laboratory. Increas- 
ingly, in the course of these studies, therapeutic interven- 
tions such as catheter ablation procedures are being per- 
formed. 
This classification is applied to three major patient 
groups: 1) patients who present with sinus node dysfunction, 
atrioventricular (AV) and intraventricular conduction delay 
or block, and supraventricular and ventricular tachycardias; 
2) patients who present with a variety of clinical problems 
including the long QT syndrome, Wolff-Parkinson-White 
abnormality without tachycardia, ventricular arrhythmias 
without tachycardia, unexplained near syncope or syncope, 
cardiac arrest and unexplained episodes of palpitation; 3) 
patients undergoing pharmacologic, electrical or ablative 
treatment of arrhythmias. Because the application of elec- 
trophysiologic studies in children on occasion differs from 
that in adults, that subject is dealt with in a separate section. 
II. Role of Electrophysiologic Study in 
Evaluating Sinus Node Function 
Sinus node dysfunction may be diagnosed electrocardio- 
graphically by the presence of persistent unexplained sinus 
bradycardia, sinus arrest or sinoatrial exit block. Sinus node 
dysfunction may be related to intrinsic sinus node disease, 
the presence of drugs that depress sinus node function (e.g., 
digitalis, beta-adrenergic blocker), autonomic imbalance 
(e.g., increased vagal tone) or a combination of these con- 
ditions. Evaluation of sinus node function requires, in addi- 
tion to the electrocardiogram, the use of drugs such as 
atropine, isoproterenol and propranolol (4). Autonomic 
blockade may help to establish the mechanism of sinus node 
dysfunction in some patients. Exercise testing and long-term 
electrocardiographic (ECG) recording are also helpful in 
assessing sinus node function (5). Carotid sinus massage 
may identify patients with sinus node dysfunction and ca- 
rotid sinus hypersensitivity. 
The indications for electrophysiologic studies have been Invasive electrophysiologic studies can be used to assess 
divided into three classes: sinus node automaticity by measuring the sinus node recov- 
Class I 
Conditions for which there is general agreement that the 
electrophysiologic study provide information that is very 
useful and important for patient management. Experts agree 
that patients with these conditions should undergo electro- 
physiologic studies. 
Class II 
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ery time and sinoatrial conduction time (6). The response to 
right atria1 pacing for 30 s at several paced rates is used to 
determine the sinus node recovery time (7). which is the 
interval between the last paced right atria1 electrogram and 
the first spontaneous sinus depolarization. Because the sinus 
node recovery time is influenced by the spontaneous sinus 
rate, the corrected sinus node recovery time, i.e., the 
difference between the sinus node recovery time and the 
spontaneous sinus cycle length before pacing, has also been 
used to evaluate sinus node automaticity. Occasionally after 
cessation of pacing, the first return cycle is of normal 
duration but the subsequent cycles may show an abrupt 
prolongation, called secondary pauses. 
Sinoatrial conduction time can be estimated indirectly 
from the responses to programmed atria1 stimulation during 
sinus rhythm or atria1 pacing at a rate just faster than the 
sinus rate (8,9). It can also be measured directly with 
extracellular electrodes placed in the area of the sinus node 
(IO). Direct and indirect measurements of sinoatrial conduc- 
tion time seem to correlate well in patients with normal sinus 
node function (6). Measurement of sinus node refractoriness 
is a potentially important method of assessing sinus node 
function but needs further evaluation (11). 
The sensitivity of the corrected sinus node recovery time 
for detecting sinus node dysfunction is 54% and that of the 
sinoatrial conduction time is approximately 51%. The com- 
bined sensitivity of both increases to 64%. Sensitivity in- 
creases in the elderly with symptomatic sinus node dysfunc- 
tion and in those showing sinoatrial exit block (12,13). The 
specificity of the two tests combined is about 88%. There- 
fore, abnormal sinus node function determined by electro- 
physiologic study should be viewed as supporting evidence 
in clinical decision making. In addition to evaluating sinus 
node function, it is important to test AV node and His- 
Purkinje function because AV conduction is frequently 
impaired in patients with sinus node disease ( 14). 
Recommendations for 
Electrophysiologic Studies 
Class I 
Symptomatic patients (with syncope or near syncope), in 
whom sinus node dysfunction is suspected as a cause of 
symptoms but a causal relation between sinus bradycardia, 
sinus pauses or sinus node exit block and the symptoms 
cannot be established by other means. 
Class II 
I. Patients who require pacemaker insertion to treat 
sinus node dysfunction, when it is necessary to assess 
anterograde and retrograde AV conduction and vul- 
nerability to atria1 tachyarrhythmias, to determine the 
appropriate site and modality of pacing. 
Patients with sinus node dysfunction, to determine the 
severity or mechanism, or both, of dysfunction (in- 
trinsic versus extrinsic) and response to drugs, infor- 
mation that may help direct therapy. 
Symptomatic patients (syncope and near syncope) 
with sinus node dysfunction, to exclude other arrhyth- 
mic mechanisms (e.g., ventricular tachycardia) as a 
cause of symptoms. 
Class III 
1. 
2. 
Symptomatic patients with sinus node dysfunction 
when symptoms are clearly related to a documented 
bradyarrhythmia. 
Asymptomatic patients with sinus bradyarrhythmia or 
sinus pauses observed during sleep. 
III. Role of Electrophysiologic Study 
In Patients With Acquired 
Atrioventricular Block 
The ECG classification of AV block include these cate- 
gories: I) First degree AV block-prolongation of the PR 
interval beyond 0.20 s. 2) Second degree AV block- 
intermittent failure to conduct a single P wave. Two types 
have been described. In type 1 second degree AV block 
(Wenckebach block) there is progressive prolongation of the 
PR interval before the blocked P wave; in type 11 block PR 
intervals are constant before the blocked P wave. AV block 
with a 2: 1 conduction ratio is not classified as either type I or 
type II. 3) Advanced AV block. Some experts recommend 
this additional category to define a condition in which 
multiple consecutive P waves are blocked but complete AV 
block is not present. 4) Complete AV block-failure of all P 
waves to conduct to the ventricle, resulting in complete 
dissociation between P waves and QRS complexes due to 
block. 
His bundle recordings allow delineation of three anatomic 
sites of AV block (15): 1) Proximal (above the His bundle), 
representing delay or block in the AV node; 2) Intra-Hisian. 
representing delay or block within the His bundle; and 3) 
Infra-Hisian or distal to the His bundle, representing block 
or delay distal to the His bundle recording site either in the 
distal His bundle or in the bundle branches. 
There are certain correlations between ECG patterns and 
the site of block (16). In type I second degree AV block with 
narrow QRS complexes, the block is usually at the level of 
the AV node; less frequently it may be within the His 
bundle. In type 1 second degree AV block with wide QRS 
complexes (bundle branch block) the block may be in the AV 
node or within or below the His bundle. Type II second 
degree AV block is usually within or below the His bundle 
and is most often seen with bundle branch block. Rarely, the 
block can be in the AV node. In complete AV block with an 
escape rhythm of narrow QRS complexes, the site of block 
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may be in the AV node or within the His bundle. In complete 
AV block with an escape rhythm and wide QRS complexes, 
the site of block may be in the AV node or within or below 
the His bundle. Clinical information regarding age, gender, 
underlying heart disease and the use of cardiac medication 
may also be helpful in predicting the site of AV block. 
Prognosis of patients with AV block depends on the site 
of block. Chronic first degree AV block, particularly AV 
node block, has a good prognosis. The abnormality is 
frequently drug related and reversible. The clinical course of 
patients with second degree AV node block is usually benign 
and the prognosis depends on the presence and severity of 
underlying heart disease (17). The prognosis of patients with 
second degree AV block within the His bundle is uncertain. 
Patients frequently manifest congestive heart failure and 
syncope. Untreated chronic second degree block below the 
His bundle has a poor prognosis; patients frequently proceed 
to higher degrees of block and become symptomatic with 
syncope (18). Patients with untreated acquired complete AV 
block are often symptomatic regardless of the site of the 
block (19). 
Recommendations for 
Electrophysiologic Studies 
Class I 
1. Symptomatic patients (with syncope or near syncope), 
in whom His-Purkinje block, suspected as a cause of 
symptoms, has not been established with ECG record- 
ings. 
2. Patients with second or third degree AV block treated 
with a pacemaker who remain symptomatic (with 
syncope or near syncope) in whom ventricular tachy- 
arrhythmia is suspected as a cause of symptoms. 
Class II 
1. Patients with second or third degree AV block, in 
whom knowledge of the site or mechanism of block, or 
both, may help direct therapy or assess prognosis. 
2. Patients with concealed junctional extrasystoles sus- 
pected as a cause of second or third degree AV block 
pattern (i.e., pseudo AV block). 
Class III 
1. 
2. 
Patients in whom the symptoms and the presence of 
AV block are correlated by electrocardiography. 
Asymptomatic patients with transient AV block asso- 
ciated with sinus slowing (e.g., nocturnal type I sec- 
ond degree AV block). 
IV. Role of Electrophysiologic Study in 
Patients With Chronic Intraventricular 
Conduction Delay 
As judged from the ECG, the intraventricular conduction 
system appears to be trifascicular, consisting of the two 
fascicles of the left bundle (anterior and posterior) and the 
right bundle branch. The anatomic basis for the trifascicular 
conduction system in humans is less clearly defined. The HV 
interval in patients with bifascicular block is a measure of the 
conduction time through the remaining functioning fascicle. 
Patients with bifascicular block and a prolonged HV interval 
(>55 ms) appear to have a slightly increased risk of devel- 
oping complete trifascicular block (20,21). Although the 
prevalence of prolonged HV interval is high, the incidence of 
complete trifascicular block is low (2% to 3% annually, but 
greater if the HV interval exceeds 100 ms) and the rate of 
progression in absence of an acute intervening event (drugs, 
electrolytes, ischemia) is slow (2&22). Thus, the HV inter- 
val has a high sensitivity (82%), but a very low specificity 
(63%) for predicting the development of complete trifascic- 
ular block (21). 
Rapid atria1 pacing has been used to improve the speci- 
ficity of electrophysiologic testing in patients with bifascic- 
ular block. A positive response consists of the development 
of block distal to the His bundle with rapid atria1 pacing 
during 1:l AV node conduction. Functional distal His block 
due to abrupt shortening of the coupling interval (such as 
during the long-short cycles of Wenckebach periods or at the 
onset of pacing) is not considered a positive response. The 
sensitivity of distal His block induced by atria1 pacing is 
relatively low but its positive predictive value for develop- 
ment of complete AV block is high (23). 
Sudden death in patients with bifascicular block cannot 
always be explained by the development of complete trifas- 
cicular block (24). There is increasing evidence that ventric- 
ular arrhythmias may play a significant role in patients with 
advanced heart disease and bifascicular block. For this 
reason, electrophysiologic evaluation of symptomatic pa- 
tients with intraventricular conduction defects should also 
include study of sinus node function and programmed atrial 
and ventricular stimulation in an attempt to induce tachyar- 
rhythmias. 
Recommendations for 
Electrophysiologic Studies 
Class I 
Symptomatic (with syncope or near syncope) patients 
with bundle branch block whose ventricular arrhythmia is 
suspected to cause the symptoms; not for study of intraven- 
tricular conduction delay itself. 
Class II 
Symptomatic patients with bundle branch block in whom 
the knowledge of the site, severity of conduction delay or 
response to drugs may help to direct therapy or assess 
prognosis. 
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Class III 
I. Asymptomatic patients with intraventricular conduc- 
tion delay. 
2. Symptomatic patients with intraventricular conduc- 
tion delay whose symptoms can be causally related to 
ECG events. 
V. Role of Electrophysiologic Study in the 
Diagnosis of Patients With a Narrow QRS 
Tachycardia (QRS complex <0.12 s) 
A narrow QRS tachycardia can be caused by rapid 
impulse formation in the sinus node (sinus node tachycar- 
dia), the atrium (atria1 tachycardia, atria1 flutter and atrial 
fibrillation), and the AV node-His bundle (AV junctional 
tachycardia), reentry within the AV node (AV node reen- 
trant tachycardia) or a circus movement using the AV 
node-His pathway for anterograde AV conduction and an 
accessory AV or nodoventricular pathway for retrograde 
conduction. Rarely, rapid impulse formation high in the 
intraventricular conduction system can lead to a ventricular 
tachycardia with a narrow QRS complex. 
Frequently, careful examination of the 12 lead ECG, 
especially when a recording during carotid sinus massage is 
also available, facilitates making the correct diagnosis. 
Proper identification of the site of origin of atria1 activity, its 
rate and its relation to ventricular rhythm is essential. 
Atria1 tachycardia typically has atria1 activity preceding 
the QRS complex, usually creating a PR interval shorter than 
the RP interval. The PR interval may vary according to AV 
node conduction and the rate of the atrial tachycardia. In 
typical AV node reentrant tachycardia, the atrium and 
ventricle are activated simultaneously, with the P wave 
hidden within the QRS complex or inscribed in the terminal 
portion of the QRS complex. In an atypical AV reentrant 
tachycardia, the P wave follows the QRS complex with an 
RP interval longer than the PR interval. When a tachycardia 
circuit is present with anterograde conduction over the AV 
node and retrograde conduction over an accessory AV or a 
nodoventricular pathway, atria1 activation follows the QRS 
complex. If the bypass fiber conducts the impulse rapidly, 
the P wave occurs shortly after the QRS complex so that the 
RP interval is shorter than the PR interval. Only a slowly 
conducting accessory AV pathway results in an RP interval 
that is longer than the next PR interval. 
Rarely AV dissociation is present during a narrow QRS 
tachycardia. Such tachycardias may originate in the AV 
node, His bundle or fascicles, or may be due to reentry using 
a circuit consisting of the AV node-His bundle antero- 
gradely and a nodoventricular fiber retrogradely, or a circuit 
with anterograde conduction through the His bundle and 
retrograde conduction through a fasciculoventricular fiber. 
The correct identification of the site of origin of a supraven- 
tricular tachycardia can be facilitated by use of a decision 
tree (25). 
Recommendutions for 
Electrophysiologic Studies 
Class I 
Patients with frequent or poorly tolerated episodes of 
tachycardia not adequately responding to drug therapy 
in whom information about site of origin. mechanism 
and electrophysiologic properties of the pathways of 
the tachycardia is essential for choosing appropriate 
therapy (drugs, catheter ablation, pacing or surgery). 
Patients who prefer ablative therapy to pharmacologic 
management (see Section XV). 
Class II 
Patients with less symptomatic but frequent episodes of 
tachycardia requiring drug treatment in whom there is con- 
cern about the effects of the antiarrhythmic drug on the sinus 
node or on AV conduction. 
Class III 
1. Patients whose 12 lead ECG gives sufficient informa- 
tion about the type of tachycardia to allow selection of 
an appropriate antiarrhythmic drug treatment. 
2. Patients whose tachycardias can easily be controlled 
by vagal maneuvers or drug therapy even in the 
absence of precise information on site of origin, mech- 
anism or pathway of the tachycardia. 
VI. Role of Electrophysiologic Study in 
Establishing the Diagnosis in Patients With 
Wide QRS Complex Tachycardias 
Wide QRS complex tachycardias can be caused by su- 
praventricular tachycardia with aberration or preexisting 
bundle branch block, ventricular tachycardia and a variety 
of pre-excitation syndromes including those using AV by- 
pass tracts anterogradely (atrial tachycardia. atria1 flutter, 
antidromic circus movement tachycardia) and, less com- 
monly, those using nodofascicular and nodoventricular by- 
pass tracts. Standard ECG guidelines to distinguish su- 
praventricular tachycardia with aberration from ventricular 
tachycardia, particularly for right bundle branch block pat- 
terns, have been established (26-29). However, criteria to 
differentiate left bundle branch block type tachycardias are 
less well defined (30). The ECG patterns of tachycardias 
with ventricular activation produced by conduction over an 
AV bypass tract cannot be distinguished from ventricular 
tachycardias originating in the base of the left ventricle on 
the basis of QRS configuration alone. Only the presence of 
AV dissociation or intermittent failure of retrograde conduc- 
tion during AV reciprocating tachycardia (antidromic) can 
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exclude an AV bypass tract. Characteristic ECG configura- 
tions of ventricular tachycardias caused by foci from various 
regions of the heart (31) or ECG patterns that cannot be 
explained on the basis of ventricular pre-excitation can also 
be used to help exclude conduction over a bypass tract. 
Thus, if possible, a 12 lead ECG during sinus rhythm should 
be used for comparison. The presence of Wolff-Parkinson- 
White syndrome or an intraventricular conduction distur- 
bance during sinus rhythm can help point to aberration. A 
preexisting intraventricular conduction disturbance during 
sinus rhythm renders many of the morphologic criteria of 
ventricular tachycardia susceptible to error. At times, a 
differential between ventricular tachycardia and aberration 
will remain in doubt. In such instances, electrophysiologic 
studies may be necessary to establish a definitive diagnosis. 
To differentiate these tachycardias, one needs to I) 
record a His deflection during the tachycardia or during 
sinus rhythm either before the onset or after the conversion 
of the tachycardia to be certain that the recording electrode 
is in an appropriate position to record a His deflection if one 
is present, 2) analyze the timing and sequence of atrial 
activation patterns during the tachycardia, and 3) assess the 
response of the His deflection (if seen) and atria1 activation 
and timing in response to ventricular stimulation during the 
tachycardia. For example, atria1 activation can be advanced 
by a premature ventricular stimulus during an AV recipro- 
cating tachycardia and at a time when the His bundle is 
refractory, thus indicating the presence of an accessory 
pathway. Supraventricular tachycardia with aberration can 
be excluded by demonstrating the absence of a His deflec- 
tion, dissociation of the His deflection from the QRS com- 
plex during the tachycardia, or the presence of a His 
deflection with an HV interval shorter than that recorded 
during sinus rhythm. An HV interval equal to or exceeding 
the HV interval recorded during sinus rhythm suggests a 
supraventricular tachycardia, provided the His deflection is 
due to anterograde and not to retrograde activation. Catheter 
position is obviously critical for the demonstration of these 
phenomena. Two unique tachycardias that may be very 
difficult to classify or diagnose, or both, are bundle branch 
reentrant tachycardia and a tachycardia using a nodofascic- 
ular bypass tract for ventricular activation. Distinguishing 
various pre-excitation syndromes from ventricular tachycar- 
dia may be difficult and requires careful analysis of atrial 
activation during the tachycardia and responses to pro- 
grammed stimulation during the tachycardia. However, be- 
cause all tachycardias involving AV bypass tracts antero- 
gradely require part of the atrium, the presence of AV 
dissociation supports a diagnosis of ventricular tachycardia. 
The differential diagnosis of these complex arrhythmias 
requires a comprehensive electrophysiologic study as well as 
a detailed analysis of the ECG (32). 
Recommendations for 
Electrophysiologic Studies 
Class I 
Patients with wide QRS complex tachycardias that are 
sustained or symptomatic, or both, when the correct diag- 
nosis is unclear and is necessary for appropriate patient care. 
Class II 
Patients with pre-excitation syndromes with suspected 
antidromic tachycardia, to evaluate the possibility of multi- 
ple bypass tracts. 
Class III 
Patients with ventricular tachycardia or supraventricular 
tachycardia with aberration or pre-excitation syndromes 
identified by ECG criteria. 
VII. Role of Electrophysiologic Study in 
Patients With a Prolonged QT 
Interval Syndrome 
Prolongation of the QT interval, with associated ventric- 
ular tachyarrhythmias, may occur chronically as a part of the 
congenital idiopathic prolonged QT interval syndrome, or 
may be acquired secondary to metabolic, toxic or patho- 
physiologic factors (33). Influence of the autonomic nervous 
system is strongly suspected in the congenital long QT 
interval syndrome. 
The role of electrophysiologic studies in the diagnosis and 
evaluation, or in guiding management, of either congenital or 
acquired forms of prolonged QT interval syndrome at 
present is limited (34). Electrophysiologic studies in patients 
with congenital long QT syndrome infrequently result in 
initiation of ventricular arrhythmias (35-37). Such studies 
are of limited or no predictive value (35). Similarly they are 
of no value in acquired forms of prolonged QT interval 
syndrome, whether or not the syndrome is associated with 
spontaneous arrhythmias (34). Some electrophysiologists 
have used electrophysiologic studies for diagnostic purposes 
in patients who have unexplained syncope or palpitation and 
also have acquired prolongation of the QT interval while 
receiving antiarrhythmic drugs. In the future, the use of 
monophasic action potential recordings may prove useful 
(37). 
Recommendations for 
Electrophysiologic Studies 
Class I 
None. 
Class II 
Identification of a proarrhythmic effect of antiarrhythmic 
drugs in patients experiencing their first episode or episodes 
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of sustained ventricular tachycardia or cardiac arrest while 
receiving an antiarrhythmic drug. 
Class III 
1. Patients with congenital QT prolongation. 
2. Patients with acquired prolonged QT syndrome with 
symptoms closely related to an identifiable cause or 
mechanism. 
VIII. Role of Electrophysiologic Study 
In Patients With the 
Wolff-Parkinson-White Syndrome 
In the Wolff-Parkinson-White syndrome, the presence of 
an accessory AV pathway leads to early activation of a part 
or the whole of the ventricle by an impulse originating in the 
sinus node or atrium. The second pathway between atrium 
and ventricle makes it possible for arrhythmias to occur. The 
two most frequently occurring arrhythmias are a circus 
movement tachycardia and atria1 fibrillation. 
During circus movement tachycardia, the impulse travels 
in a circuit consisting of atrium 3 AV node j His bundle j 
bundle branch + ventricle + accessory pathway 3 atrium. 
A circus movement tachycardia with AV conduction over 
the AV node and ventriculoatrial (VA) conduction over the 
accessory AV pathway is referred to as orthodromic. A 
tachycardia conducting in the reverse direction (AV conduc- 
tion over the accessory pathway and VA conduction over 
the His-AV node) is referred to as antidromic circus move- 
ment tachycardia. Essential for the occurrence of a circus 
movement tachycardia is temporary or permanent unidirec- 
tional block in one of the two AV pathways. This can occur 
with a critically timed atria1 or ventricular premature com- 
plex, by reaching a critical sinus rate, or after the adminis- 
tration of a drug. 
Atria1 jhrillution in patients with the Wolff-Parkinson- 
White syndrome can prove to be an extremely serious 
arrhythmia in the setting of an accessory pathway with a 
short anterograde refractory period. In that situation the 
occurrence of ventricular fibrillation has been documented. 
The electrophysiologic properties of the accessory pathway 
are an important determinant of the incidence and rate of a 
circus movement tachycardia and of the ventricular rate 
during atria1 fibrillation. Electrophysiologic studies give in- 
formation about the electrophysiologic properties of the 
accessory pathways and their locations that may help direct 
therapy. 
Recommendations for 
Electrophysiologic Studies 
Class I 
Patients considered for nonpharmacologic treatment (ac- 
cessory pathway interruption or antitachycardia pacing), 
because of life-threatening or incapacitating arrhythmias or 
drug intolerance. 
Class II 
Patients with arrhythmias requiring treatment in whom 
information about the type of arrhythmia, localization, 
number and electrophysiologic properties of one or 
more accessory AV pathways and the effect of antiar- 
rhythmic drugs may influence selection of the most 
appropriate treatment. 
Asymptomatic patients with ECG evidence of Wolff- 
Parkinson-White syndrome during sinus rhythm, in 
whom knowledge of electrophysiologic characteristics 
of the accessory pathway may help in guidance of 
future participation in high risk occupations or activi- 
ties. 
Patients with Wolff-Parkinson-White syndrome and a 
family history of premature sudden death. 
Patients with Wolff-Parkinson-White syndrome who 
are undergoing cardiac surgery for other reasons. 
Class III 
Asymptomatic persons without arrhythmias who are not 
in class II-2 or 11-3. 
IX. Role of Electrophysiologic Study in 
Patients With Ventricular Premature 
Complexes and Couplets 
The presence of high grade ventricular ectopic activity in 
patients with coronary artery disease and left ventricular 
dysfunction is associated with increased risk for sudden 
death and cardiovascular mortality (38-40). However, the 
causal role of ventricular ectopic activity and sudden cardiac 
death remains controversial. Even though the ventricular 
ectopic complexes in themselves do not produce serious 
symptoms. they are often treated with the assumption that 
such abnormalities represent warning arrhythmias. To date, 
no studies have demonstrated that suppression of ventricular 
premature complexes with antiarrhythmic agents reduces 
the incidence of sudden cardiac death, and preliminary data 
for the Cardiac Arrhythmia Suppression Trial suggest that 
treatment with some antiarrhythmic drugs after myocardial 
infarction may be harmful (40A). Because not all patients 
with a combination of complex ventricular ectopic activity 
and organic heart disease have the same risk for sudden 
cardiac death, attempts have been made to stratify these 
patients into low and high risk groups. One such approach 
utilizes electrophysiologic studies to separate patients into 
groups with and without electrically inducible ventricular 
tachycardia and to use this response to stratify patients into 
high and low risk groups, respectively (41). However, there 
are no randomized studies available to support the validity of 
such a stratification. Therefore, the clinical value of such 
studies in this patient population with complex ventricular 
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ectopic activity and organic heart disease (excluding recent fibrillation with an aggressive stimulation protocol may be 
myocardial infarction) remains controversial. nonspecific findings. 
Recommendations for 
Electrophysiologic Studies 
Class I 
None. 
Class II 
Patients with premature ventricular complexes and unex- 
plained presyncope or syncope. (See section on “Unex- 
plained Syncope.“) 
The results of electrophysiologic studies also suggest 
that, in patients with underlying structural heart disease such 
as prior myocardial infarction, an arrhythmia is more likely 
to be the cause of syncope. Conversely, in patients without 
structural heart disease and a normal ECG, the diagnostic 
yield of electrophysiologic studies is relatively low (44). 
Patients with no abnormalities noted during electrophysio- 
logic studies have a low incidence of sudden death during 
follow-up, suggesting a possible prognostic value of a nega- 
tive test. 
Class III 
Asymptomatic patients with premature ventricular com- 
Recommendations for 
plexes. 
Electrophysiologic Studies 
Class I 
X. Role of Electrophysiologic Study in 
Patients With Unexplained Syncope 
Syncope and near syncope are frequent medical prob- 
lems. Despite a detailed history, physical examination and 
neurologic study, the etiology remains obscure in about 50% 
of cases (42). Because various noninvasive methods are 
often ineffective in identifying the underlying etiology, elec- 
trophysiologic studies have more recently been utilized to 
detect arrhythmias as a possible cause (43-51). A 12 lead ECG 
alone is unlikely to provide a clue to the etiologic diagnosis. 
However, it may yield insight into the nature of underlying 
structural heart disease, if present. The subsequent direction 
of evaluation generally depends on the clues obtained during 
the initial diagnostic studies. Among the cardiac causes of 
syncope, arrhythmias are a frequent consideration. Long- 
term ambulatory ECG monitoring, tilt table testing or exer- 
cise testing, alone or in combination, are performed before 
electrophysiologic studies are instituted. Because syncopal 
and presyncopal episodes are sporadic, continuous 24 to 48 h 
ambulatory records are generally unrewarding. Electrophys- 
iologic studies can often initiate clinically important arrhyth- 
mias and are a natural extension for arrhythmia evaluation in 
patients with unexplained syncope. 
Attempts are made to assess sinus node dysfunction, the 
presence of His-Purkinje block and the induction of su- 
praventricular as well as ventricular tachycardias. The most 
common abnormality induced is ventricular tachycardia. 
Less frequently, His-Purkinje block and sinus node dys- 
function are encountered. The studies suggest that induction 
of sustained monomorphic ventricular tachycardia, His- 
Purkinje block and evidence of sinus node dysfunction may 
have diagnostic value. Induction of rapid nonsustained 
monomorphic ventricular tachycardia and of supraventricu- 
lar tachycardia when associated with hypotension may also 
prove clinically important. On the other hand, induction of 
atria1 fibrillation, polymorphic ventricular tachycardia- 
Patients with unexplained syncope and known or sus- 
pected structural heart disease. 
Class II 
Patients with unexplained syncope but without structural 
heart disease. 
Class III 
Patients with known cause of syncope. 
XI. Role of Electrophysiologic Study in 
Survivors of Cardiac Arrest 
Patients resuscitated from cardiac arrest without a new Q 
wave myocardial infarction are at high risk for recurrent 
cardiac arrest and sudden death after discharge (52-56). In 
this group, the 1 and 2 year rate of recurrence of cardiac 
arrest is approximately 30% and 45%, respectively (52,54). 
The recurrence rate appears to be declining because of 
aggressive therapy of the arrhythmias and the underlying 
ischemic heart disease (57). 
In the absence of antiarrhythmic drug therapy, ventricu- 
lar tachyarrhythmias can be initiated during electrophysio- 
logic studies in 70% to 80% of patients resuscitated from 
cardiac arrest. Of these, sustained monomorphic ventricular 
tachycardia constitutes 36% to 51%. The remaining rhythms 
include polymorphic ventricular tachycardia degenerating to 
ventricular fibrillation or nonsustained ventricular tachycar- 
dia (58-63). Sustained monomorphic ventricular tachycardia 
or ventricular tachycardia degenerating into ventricular fi- 
brillation is an acceptable therapeutic end point, whereas 
nonsustained ventricular tachycardia as a guide to therapy is 
a more controversial end point. 
Identification of a drug efective in suppression of induc- 
ible ventricular tachycardia orfibrillation has been reported 
in 26% to 80% of survivors of cardiac arrest (58-63). Such a 
response predicts suppression of ventricular tachycardia, 
ventricular fibrillation and prevention of sudden death during 
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long-term follow-up (63). Although some patients whose 
arrhythmia remains inducible may not have a spontaneous 
recurrence, survivors of cardiac arrest with ventricular 
tachycardia or ventricular fibrillation still inducible at the 
time of hospital discharge are at significantly higher risk for 
recurrent cardiac arrest and sudden death (estimated risk 
23% at 1 year and 30% at 3 years). Patients whose arrhyth- 
mias have been suppressed by drugs or surgery, or both, 
have an estimated risk for recurrence of sudden death and 
cardiac arrest of 6% at 1 year and 15% at 3 years; p = 0.004 
(63) (see section XIII on Role of Electrophysiologic Study to 
Guide Drug Therapy). Cardiac arrest survivors whose ar- 
rhythmia remains electrically inducible despite drug treat- 
ment may be considered for nonpharmacologic treatment 
alternatives including surgery and automatic implantable 
defibrillators. 
Failure to induce ventricular arrhythmias during baseline 
electrophysiologic studies in the absence of antiarrhythmic 
drugs in survivors of cardiac arrest is associated with a 
variable prognosis. Patients with depressed left ventricular 
function in whom no obvious reversible cause of the arrhyth- 
mia can be identified, e.g., ischemia, remain at significant 
risk for recurrent cardiac arrest (58-64). 
Guidance of therapy by electrophysiologic studies is 
indicated in the majority of survivors of cardiac arrest, 
especially in those with infrequent spontaneous ventricular 
arrhythmias, and it is generally accepted as the first ap- 
proach to management when available. 
Recommendations for 
Electrophysiologic Studies 
Class I 
1. Patients surviving an episode of cardiac arrest without 
evidence of an acute Q wave myocardial infarction. 
2. Patients surviving an episode of cardiac arrest occur- 
ring ~48 h after acute myocardial infarction. 
Class II 
Patients surviving a cardiac arrest due to a bradyarrhyth- 
mia. 
Class III 
1. Patients with cardiac arrest occurring only within the 
first 48 h of acute myocardial infarction. 
2. Patients with cardiac arrest resulting from acute re- 
versible ischemia or another clearly identifiable cause 
(e.g., aortic stenosis, congenital long QT syndrome). 
XII. Role of Electrophysiologic Study in 
Patients With Unexplained Palpitation 
Long-term ambulatory recording is the most useful pro- 
cedure to document the cardiac rhythm associated with 
palpitation (65). The recording can be a continuous 24 h 
recording or can be intermittent. Electrophysiologic studies 
are used only if repeated recording attempts fail to provide 
an answer. The sensitivity of electrophysiologic studies is 
low in patients with unexplained palpitation. 
Recommendations for 
Electrophysiologic Studies 
Class I 
Patients with palpitation who have a pulse rate that has 
been documented by medical personnel to be inappropri- 
ately rapid (e.g., >150 beats/min) and in whom ECG record- 
ings fail to document the cause of the symptoms. 
Class II 
Patients with clinically significant palpitations, suspected 
to be of cardiac origin, in whom the symptoms are sporadic 
and cannot be documented despite repeated long-term ECG 
or event recordings, to determine the mechanism of arrhyth- 
mias, direct the therapy or assess prognosis. 
Class III 
Patients with palpitation due to extracardiac causes (e.g., 
hyperthyroidism). 
XIII. Role of Electrophysiologic Study to 
Guide Drug Therapy 
Electrophysiologic studies have been used in patients 
with a variety of electrically inducible cardiac arrhythmias to 
predict antiarrhythmic drug efficacy. After inducibility is 
documented, the drug to be evaluated is administered, 
preferably orally, and electrical stimulation is repeated. In 
general, if the drug prevents electrical induction of the 
arrhythmia, a prediction of drug efficacy is made; if the 
arrhythmia remains inducible, the drug will most likely not 
prove efficacious. 
Ventricular arrhythmias. The use of electrophysiologic 
studies to test drug efficacy is feasible for most drugs in 
patients with documented, sustained, monomorphic ventric- 
ular tachycardia (66) and in survivors of cardiac arrest (67). 
The data strongly suggest that electrophysiologic studies are 
the method of choice to assess drug efficacy in patients who 
have inducible ventricular tachyarrhythmias but insufficient 
spontaneous ventricular arrhythmias to allow assessment by 
serial long-term ECG recordings. A similar approach can be 
used in some patients with nonsustained ventricular tachy- 
cardia (68.69). 
Some patients develop their first episode of sustained 
ventricular tachycardia or cardiac arrest while receiving an 
antiarrhythmic drug. Failure to induce ventricular tachyar- 
rhythmia after withdrawal of the antiarrhythmic drug in 
these patients and presence of inducibility with reintroduc- 
tion of the drug suggest that the arrhythmia was exacerbated 
or provoked by the drug (70). 
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Supraventricular arrhythmias. In patients with the Wolff- 
Parkinson-White syndrome who have circus movement 
tachycardia utilizing the AV node and accessory pathway, 
prevention of tachycardia induction by drug administration 
predicts long-term efficacy. In patients with the Wolff- 
Parkinson-White syndrome who have atria1 fibrillation with 
anterograde conduction over the accessory pathway, most, 
although not all, investigators believe that complete block of 
anterograde conduction over the accessory pathway, 
marked lengthening of the anterograde refractory period of 
the accessory pathway and a marked reduction in the 
ventricular response to induced atria1 fibrillation conducted 
over the accessory pathway are predictive of a therapeutic 
success (7 1,72). Induction of tachycardia after isoproterenol 
challenge may improve prediction of drug efficacy. 
Limited data suggest that drug efficacy may be predicted 
by response to electrophysiologic studies in selected patients 
with AV node reentrant tachycardia (73). Prevention of 
electrical induction of the atria1 fibrillation may predict 
long-term suppression of spontaneous atria1 fibrillation (74). 
There is no documentation of prediction of drug efficacy 
based on electrophysiologic studies in patients with induc- 
ible sinoatrial node reentry, intraatrial reentry and ectopic 
atria1 tachycardias. Multifocal atria1 tachycardia, isolated 
premature atria1 complexes and other less common atria1 
arrhythmias are not inducible by electrophysiologic studies. 
Specific antiarrhythmic drugs. Programmed electrical 
stimulation is useful in assessing efficacy of most drugs 
approved for use in the United States. The utility of electro- 
physiologic studies in assessing efficacy of amiodarone is 
controversial (75-78). Though prevention of ventricular 
tachyarrhythmia induction by amiodarone is a highly accu- 
rate predictor of long-term efficacy, many patients whose 
ventricular tachyarrhythmia continues to be inducible de- 
spite therapy with amiodarone may remain asymptomatic 
and free of arrhythmias. The likely prevention of sudden 
death by amiodarone in face of continuing arrhythmia induc- 
ibility can be anticipated when the induced arrhythmia is 
associated with a slower rate and absence of hemodynamic 
deterioration (76). Each new antiarrhythmic drug must be 
evaluated individually to determine whether electrophysio- 
logic studies can be used to predict its efficacy in suppression 
of spontaneous arrhythmias. 
Recommendations for 
Electrophysiologic Studies 
Class I 
1. Sustained ventricular tachycardia or cardiac arrest due 
to ventricular tachycardia or ventricular fibrillation not 
associated with the long QT syndrome or appearing 
within 48 h of an acute myocardial infarction, espe- 
cially if spontaneous premature ventricular complexes 
are too infrequent to permit use of long-term ECG 
recordings. 
Wolff-Parkinson-White syndrome with atria1 fibrilla- 
tion associated with a rapid ventricular response, a 
short bypass anterograde refractory period, or cardiac 
arrest; or with recurrent, symptomatic circus move- 
ment tachycardia unresponsive to empiric antiarrhyth- 
mic therapy. 
AV node reentrant tachycardia unresponsive to em- 
piric antiarrhythmic therapy. 
Class II 
1. 
2. 
3. 
4. 
5. 
Recurrent, symptomatic paroxysmal atria1 fibrillation 
not prevented by empiric antiarrhythmic therapy. 
Recurrent, symptomatic, inducible sinoatrial node re- 
entry, intraatrial reentry and ectopic atria1 tachycardia 
unresponsive to empiric therapy. 
Recurrent, nonsustained ventricular tachycardia not 
associated with acute myocardial infarction or the long 
QT syndrome. 
Identification of a proarrhythmic effect of antiarrhyth- 
mic drugs in patients experiencing their first episode or 
episodes of sustained ventricular tachycardia or car- 
diac arrest while receiving an antiarrhythmic drug. 
Risk stratification and consideration for therapy of the 
postmyocardial infarction patient with reduced left 
ventricular function, frequent premature ventricular 
complexes or episodes of nonsustained ventricular 
tachycardia, or both, especially if the signal-averaged 
ECG shows the presence of late potentials. 
Class III 
1. 
2. 
3. 
4. 
5. 
Isolated premature atria1 or ventricular complexes. 
Multifocal atria1 tachycardia. 
Ventricular tachycardia or cardiac arrest occurring 
only in the acute phase of myocardial infarction (~48 
h). 
Asymptomatic, nonrecurrent, or drug-responsive su- 
praventricular or nonsustained ventricular tachyar- 
rhythmias. 
Ventricular arrhythmias associated with the congenital 
long QT interval syndrome. 
XIV, Role of Electrophysiologic Study in 
Patients Who Are Candidates for 
Implantable Electrical Devices 
Application. Use of electrical devices to manage patients 
with tachycardia includes provision of rate support when 
symptomatic bradycardia results from therapy for tachycar- 
dia, e.g., sinus bradycardia as a side effect of drug adminis- 
tration or heart block after His bundle ablation; prevention 
of tachycardia onset, e.g., pacing at normal rates to treat 
complete AV heart block or other bradyarrhythmias that 
appear to cause ventricular tachyarrhythmia, pacing to sup- 
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press selected tachyarrhythmias such as torsade de pointes, 
pacing at short AV intervals to prevent AV node or AV 
reentrant tachycardias, and rapid atria1 pacing to initiate an 
atria1 tachyarrhythmia with a high degree of AV block to 
suppress a slower atria1 tachycardia that produced a more 
rapid ventricular rate; and termination of tachycardia by 
pacing, cardioversion or defibrillation (79). 
Devices. Available devices to treat patients with symp- 
tomatic bradycardias encompass the complete range of 
single and dual chamber pacemakers, including rate- 
adapting units. Pacemakers used to prevent tachycardias 
depend on the mechanism of the arrhythmia and range from 
single chamber units that deliver stimuli at normal or fast 
rates to more complex pacemakers that can pace the atrium 
and ventricle simultaneously or at short AV intervals. 
Electrical devices that terminate tachycardias by pacing 
are capable of delivering stimuli at multiple rates and ca- 
dences, depending on the tachycardia and its rate (80,81). 
Because pacing for ventricular tachycardia may accelerate 
the tachycardia or produce ventricular flutter or ventricular 
fibrillation and because the primary arrhythmia may be a 
rapid ventricular tachycardia that cannot be terminated by 
pacing, or may be ventricular flutter or ventricular fibrilla- 
tion, devices must be able to both cardiovert and defibrillate. 
Although a transvenous device capable of cardioverting 
ventricular tachycardia has been tested in humans (82). the 
device most widely used is the automatic implantable car- 
dioverter-defibrillator (83). It detects arrhythmia by ventric- 
ular rate or a probability density function. Cardioversion or 
defibrillation is achieved by a 25 to 35 J shock usually 
delivered over two epicardial patches. The device does not 
have pacing capabilities. Although important complications 
have been noted (84), the arrhythmic mortality rates are very 
satisfactory (85). Efforts to reduce defibrillation thresholds. 
such as using sequential shocks, may permit implantation of 
smaller devices (86). Subsequent devices will combine 
bradycardia and competitive antitachycardia pacing. low 
energy synchronous cardioversion and high energy defibril- 
lation capabilities in one unit. Devices will be fully program- 
mable and will deliver programmed therapy in response to 
the patient’s tachyarrhythmia. 
Patient evaluation. All patients being considered for 
treatment of a tachycardia with an electrical device must 
undergo thorough electrophysiologic studies preceding de- 
vice implantation to determine 1) a specific mechanism and 
rate of the tachycardia; 2) the most appropriate site for 
antiarrhythmic stimulation; 3) the most effective stimulation 
sequence for termination; 4) the reproducible safety and 
efficacy of the therapy: 5) the potential for acceleration or 
induction of atrial or of ventricular tachyarrhythmias; 6) 
sensing and pacing characteristics during tachycardia; and 7) 
accurate automatic arrhythmia detection. Capability of the 
device to cardiovert ventricular tachycardia and defibrillate 
ventricular fibrillation must be demonstrated in patients with 
these tachyarrhythmias. Defibrillation testing must be per- 
formed in all patients with ventricular tachyarrhythmias, 
even in those who have never experienced an episode of 
spontaneous ventricular fibrillation, because electrical ther- 
apy of ventricular tachycardia may provoke ventricular 
fibrillation that the device must then be able to terminate. An 
exercise test is useful to determine the rate of the patient’s 
sinus tachycardia that might inappropriately trigger the 
device. 
Recommendations .for 
Electrophysiologic Studies 
Class I 
1. All patients who are candidates for implantation of an 
electrical device to treat arrhythmias. 
2. All patients in whom such an electrical device is 
already implanted and in whom changes in therapy are 
contemplated that may influence the safety or efficacy 
of the device. 
Class I1 
I. 
1 
I .  
Patients with an antitachycardia device to confirm 
acceptable device function during follow-up. 
Patients who receive antibradycardia devices to test 
for the most appropriate pacing site or sites and the 
capability of atrioventricular and ventriculoatrial con- 
duction. 
Class III 
Patients who are not candidates for implantable electrical 
devices. 
XV. Role of Electrophysiologic Study in 
Patients Who Are Candidates for Ablative 
Therapy of Cardiac Arrhythmias 
Surgical management of tachycardias may be considered 
a reasonable option to long-term antiarrhythmic drugs (e.g., 
young patients with Wolff-Parkinson-White syndrome) and 
in some instances the best option for long-term survival 
(e.g.. recurrent ventricular tachycardia early after acute 
infarction). These surgical procedures may be divided into: 
1) direct procedures that involve resection or ablation of the 
specific sites in the heart that are responsible for the genesis 
of the tachyarrhythmia or constitute a critical component of 
the tachycardia pathway; 2) indirect procedures such as 
ablation of the AV node or His bundle to control the 
ventricular response to a variety of atria1 arrhythmias: and 3) 
specific procedures that isolate or exclude all or part of the 
cardiac chamber of arrhythmia origin from the rest of the 
heart (87.88). 
The recent development of catheter ablation of the AV 
junction has eliminated the need for intraoperative surgical 
ablation of the AV junction in 85% or more of cases. Surgical 
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resection and ablation procedures have been used to disrupt 
AV bypass tracts in the Wolff-Parkinson-White syndrome 
for almost 20 years. With use of either an epicardial or an 
endocardial approach to the bypass tract, a success rate in 
excess of 90% and close to zero mortality is expected 
(88-90). 
Electrophysiologically directed surgical procedures for 
drug-refractory recurrent sustained ventricular tachycardia 
in the setting of chronic ischemic heart disease have also 
evolved, resulting in freedom from recurrent tachycardias in 
70% to 90% of surgical survivors with (30%), or without 
(70%), antiarrhythmic drugs (87,88,91-95). A more limited 
experience has been reported in patients with drug-resistant 
atria1 tachycardias, AV node reentrant supraventricular 
tachycardia (96), atria1 flutter and fibrillation, and ventricular 
tachycardia unrelated to ischemic heart disease, particularly 
that after repair of tetralogy of Fallot (87,88). 
anatomic landmarks to provide guidance for a more wide- 
spread surgical procedure. Such techniques include endocar- 
dial or subendocardial encircling ventriculotomy, encircling 
endocardial cryoablation and total subendocardial resection 
(87,88,90,108). These latter techniques theoretically do not 
need map guiding and can be successful in selected patients. 
However, if possible, mapping and localization of the tachy- 
cardia are preferred because 1) approximately 15% of tachy- 
cardias do not originate from areas with fractionated elec- 
trograms found during sinus rhythm (103) or from visible 
scar, 2) resection or destruction of unnecessary tissue (e.g., 
papillary muscles) may be avoided, and 3) anatomic land- 
marks to guide surgery may not be present, for example, in 
patients with recent myocardial infarction. 
Localization and mapping of arrhythmias. All patients 
undergoing surgery for recurrent arrhythmias require some 
form of electrophysiologic studies determined by the type of 
arrhythmia and the method of surgical correction. The 
purpose of the electrophysiologic studies is to determine the 
probable mechanism of the arrhythmia, the components of 
the circuit and the localization of the substrate. Attempts at 
localization should take place both during preoperative 
electrophysiologic studies and at the time of surgery 
(87,95,97,98). Localization by catheter techniques in the 
electrophysiologic laboratory are necessary because 1) the 
arrhythmia or arrhythmias may not be inducible in the 
operating room, 2) only nonmappable arrhythmias may be 
induced intraoperatively (e.g., polymorphic ventricular 
tachycardia or ventricular fibrillation), 3) not all arrhythmias 
observed spontaneously or induced by preoperative electro- 
physiologic studies are induced in the operating room, 4) 
rapid interpretation of intraoperative data may be difficult, 
and 5) intraoperative catastrophes may preclude induction or 
mapping, or both, of arrhythmias. Intraoperative localiza- 
tion procedures are important to define more precisely the 
arrhythmogenic substrate to be approached surgically and 
to localize additional pathways in patients with Wolff- 
Parkinson-White syndrome or multiple tachycardias in pa- 
tients with ventricular tachycardia (87,93,99-102). 
Atria1 tachycardias require both catheter and intraopera- 
tive mapping. Should the tachycardia be not inducible, and 
therefore not mappable, one should initially consider AV 
junctional ablation as an alternative. 
It is commonly agreed that all patients who undergo 
surgical therapy for arrhythmias should have postoperative 
electrophysiologic studies to evaluate the results of surgery. 
Recommendations for 
Electrophysiologic Studies 
Class I 
1. Patients in whom antiarrhythmic surgery or other 
ablative procedures are contemplated. 
2. Patients who have had antiarrhythmic surgery or other 
ablative procedures to assess efficacy of the procedure 
and need for further therapy. 
Class II 
Patients with symptoms compatible with arrhythmias 
having a known anatomic substrate suitable for surgical or 
other ablative procedures (e.g., aneurysms, postoperative 
tetralogy of Fallot, Wolff-Parkinson-White syndrome). 
Class III 
Patients with arrhythmias who are not candidates for 
surgical or other ablative procedures. 
Mapping the site of origin of ventricular tachycardia may 
be difficult. Mapping during sinus rhythm to identify poten- 
tially arrhythmogenic areas by finding abnormal fractionated 
or late potentials, or both, may be inaccurate (87,93,103- 
105). Pace-mapping may be useful (102,106,107). Catheter 
and intraoperative mapping are highly accurate in identifying 
the site of bypass tracts in the Wolff-Parkinson-White syn- 
drome . 
XVI. Role of Electrophysiologic Study in 
Children: Differences From Adults 
The performance and interpretation of intracardiac elec- 
trophysiologic studies in children are generally similar to 
those in adults. The indications for electrophysiologic stud- 
ies in children are also similar to the general categories in 
adults. However, there are areas in which there are some 
differences. 
Because of the limitations in accuracy and reproducibility Need for sedation. Small children, and even adolescents, 
of mapping in patients with ventricular tachycardia, different require sedation. The electrophysiologic effects of sedation 
surgical techniques are utilized that do not specifically can be vagolytic (meperidine and promethazine) or sympa- 
localize and resect the arrhythmogenic area but use visible thomimetic (ketamine). The “physiologic” conditions may 
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change throughout a study in a child with the addition of 
different types of sedation as well as a different state of 
wakefulness. For this reason, the tests of sinus node and AV 
conduction as well as refractory periods of accessory con- 
nections may be less reproducible in children than in adults. 
Prognostic testing in “high risk” groups. Some children. 
such as those who have had repair of congenital heart 
disease (109-I 12), are thought to be at high risk for arrhyth- 
mic death. No randomized studies have been carried out to 
answer this question. Some pediatric cardiologists have 
advocated the use of electrophysiologic studies in an attempt 
to identify patients who may be at higher risk for sudden 
death. Additionally, children believed to have an otherwise 
normal heart who have ventricular tachycardia induced in 
the electrophysiology laboratory may also be at risk for 
arrhythmic death. The use of electrophysiologic studies in 
such patients remains controversial (113). 
Incessant supraventricular tachycardia. Incessant su- 
praventricular tachycardias may lead to cardiomyopathy 
that occasionally is severe enough to require cardiac trans- 
plantation (114). The major causes are atrial automatic 
tachycardia and the permanent form of junctional recipro- 
cating tachycardia. These are relatively rare in adults but 
more common in children and may be confused with sinus 
tachycardia. In a child with congestive cardiomyopathy 
believed to have “sinus tachycardia,” it may be important to 
perform electrophysiologic mapping to distinguish chronic 
atria1 tachycardia from sinus tachycardia. Electrophysio- 
logic studies mapping followed by surgical ablation has 
resulted in return of normal cardiac function (115). 
Complete AV block. Congenital complete AV block most 
often occurs with a narrow QRS escape rhythm. Electro- 
physiologic studies have not been demonstrated to be clini- 
cally useful in this situation. However, if congenital com- 
plete AV block occurs with a wide QRS escape rhythm, such 
studies could provide data to determine the site of block and 
presence of infranodal disease. Acquired complete AV block 
in children is considered an indication for a permanent 
pacemaker (116). and electrophysiologic studies are not 
necessary. Electrophysiologic studies have not been demon- 
strated to be beneficial in predicting prognosis in asymptom- 
atic patients with surgically acquired bifascicular block. 
Recommendations for 
Electrophysiologic Studies 
Class I 
1. 
2. 
Patients similar to those described in the sections on 
adults. 
Patients with an undiagnosed “narrow QRS” tachy- 
cardia that cannot be distinguished from sinus tachy- 
cardia. 
Class II 
1. Patients similar to those described in the sections on 
adults. 
2. Asymptomatic patients possibly at “high risk” for 
sudden arrhythmic death such as those with postoper- 
ative congenital heart disease or a normal heart with 
complex ventricular arrhythmias. 
3. Patients with congenital complete AV block and wide 
QRS escape rhythm. 
Class III 
I. 
2. 
1 
4. 
5. 
6. 
7 
I. 
8  
9 
10. 
II. 
I?. 
Patients similar to those described in the sections on 
adults. 
Patients with congenital complete AV block and nar- 
row QRS escape rhythm. 
Patients with acquired complete AV block, 
Asymptomatic patients with surgically induced bifas- 
cicular block. 
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